|  |
| --- |
| Service Specification Checklist |
| Substance Misuse (Turning Point) |
| Time-line & Next Steps  | The LPC will make this service participation rating available to contractors by April 2023. |
| Commissioners response to LPC  | Feedback:Please forward any comments to myra@suffolklpc.org.uk  |
| Rationale of Checklist The LPC’s purpose is to work positively with commissioners to ensure high quality outcomes from the services, which are both professional and commercially viable for contractors to deliver. This rating will be shared with contractors and the service commissioner for consideration.  |
| **Point Covered**  |  |
| Notes | Action |
| **Service Outline** |
| Payment structure &system | **Supervison:** Methadone £1.30Espranor £1.85Buprenorphine £1.85**Needle Exchange:**Per transaction £1.3010p per return**Naloxone:** £15 initial supply, £5 re-supply |
| Are reporting systems suitable to all contractors? | Yes - PharmOutcomes licensed by Public Health |
| Equipment required & whoprovides/calibrates/services this? Does remuneration sufficiently cover the cost? | Medicines provided from pharmacy stock. **Branded generics are now being introduced which will reduce the remuneration overall for pharmacies due to a loss in retained margin.**Needle exchange packs provided by Turning Point via Frontier.Naloxone packs ordered by pharmacy. |
| Training required | Needle exchange & Supp. Cons. -CPPE Declaration of Competence for:Pharmacy Needle Exchange ProgrammeSubstance Use and Misuse CPPE packNaloxone – as above + additional training provided. |
| **Is/does the Service.....** |  |
| Sustainable? | Change to branded generics adds complexity and leads to loss of retained margin. |
| Clinically sound and in line with appropriate National or local guidance? | Yes |
| Enhance patient care? | Contractors have raised safety concerns over communication flow |
| Have suitable monitoring arrangements? | As above – hard to contact |
| Enhance relationships with other HCPs? | Limited support out of hours and when issues arise. |
| Deliverable? | Yes |
| Attractive enough for contractors to consider it worthwhile? | This will depend on the demographic of the patient population each pharmacy serves. **The use of branded generics will have an impact on** **whether contractors chose to deliver the service.** |
| Have performance criteria that supports a quality service? | Yes |
| Miscellaneous Information |  |
| Any other information specific to this service. | The LPC will be working with Turning Point going forwards to assess the viability of this service and to look at other components of Care that could be introduced to support this patient cohort. |
| Suggested RAG Rating |  |